Jaime Blais
Overview
Explore the profile of Jaime Blais including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sarraju A, Bakris G, Cannon C, Cherney D, Damaraju C, Figtree G, et al.
J Am Coll Cardiol
. 2022 Oct;
80(18):1721-1731.
PMID: 36302584
Background: People with type 2 diabetes mellitus (T2DM) have elevated cardiovascular (CV) risk, including for hospitalization for heart failure (HHF). Canagliflozin reduced CV and kidney events in patients with T2DM...
2.
Rodriguez F, Lee D, Gad S, Santos M, Beetel R, Vasey J, et al.
Adv Ther
. 2021 Jul;
38(8):4425-4441.
PMID: 34254257
Introduction: People with type 2 diabetes mellitus (T2DM) and diabetic kidney disease (DKD) have increased morbidity and mortality risk. Angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) are...
3.
Durkin M, Blais J
Diabetes Ther
. 2020 Dec;
12(2):499-508.
PMID: 33340064
Introduction: Diabetes is a common cause of end-stage kidney disease leading to dialysis or kidney transplantation. Estimated glomerular filtration rate (eGFR) measures kidney function, and differences in the rate (slope)...
4.
Neuen B, Ohkuma T, Neal B, Matthews D, de Zeeuw D, Mahaffey K, et al.
Am J Kidney Dis
. 2020 Sep;
77(1):23-34.e1.
PMID: 32971190
Rationale & Objective: Canagliflozin reduces the risk for cardiovascular and kidney outcomes in type 2 diabetes. This study aimed to assess the relative and absolute effects of canagliflozin on clinical...
5.
Willey C, Kamat S, Stellhorn R, Blais J
Kidney Dis (Basel)
. 2019 Apr;
5(2):107-117.
PMID: 31019924
Background: This study addresses an important gap, as it is the first US nationwide, epidemiologic study of ADPKD incidence and prevalence. Summary: This 3-year, observational study utilized data from Truven...
6.
Grantham J, Chapman A, Blais J, Czerwiec F, Devuyst O, Gansevoort R, et al.
Nephrol Dial Transplant
. 2016 May;
32(6):969-975.
PMID: 27190355
Background: Autosomal-dominant polycystic kidney disease (ADPKD) is characterized by multitudes of expanding renal cysts associated with mononuclear interstitial infiltrates. Monocyte chemotactic protein-1 is produced in the kidneys and excreted in...
7.
Phillips M, Basa-Dalay V, Blais J, Bothamley G, Chaturvedi A, Modi K, et al.
Tuberculosis (Edinb)
. 2012 Jun;
92(4):314-20.
PMID: 22647661
Rationale: Volatile organic compounds (VOCs) in breath provide biomarkers of tuberculosis (TB) because Mycobacterium tuberculosis manufactures VOC metabolites that are detectable in the breath of infected patients. Objectives: We evaluated...
8.
Wang H, Blais J, Ron D, Cardozo T
Chem Biol Drug Des
. 2010 Nov;
76(6):480-95.
PMID: 21070610
The unfolded protein response (UPR) is a coordinated program that promotes cell survival under conditions of endoplasmic reticulum stress and is required in tumor progression as well. To date, no...
9.
Zito E, Chin K, Blais J, Harding H, Ron D
J Cell Biol
. 2010 Mar;
188(6):821-32.
PMID: 20308425
Mammals have two genes encoding homologues of the endoplasmic reticulum (ER) disulfide oxidase ERO1 (ER oxidoreductin 1). ERO1-beta is greatly enriched in the endocrine pancreas. We report in this study...
10.
Blais J, Bell J
Cell Cycle
. 2007 Jan;
5(24):2874-7.
PMID: 17218786
Oxygen supports the life of all aerobic organisms and virtually every cell type is capable of sensing decreased tissue oxygenation or hypoxia. Hypoxic microenvironments are known to exist within developing...